Publications in collaboration with researchers from Hannover Medical School (12)

2024

  1. Risk loci involved in giant cell arteritis susceptibility: a genome-wide association study

    The Lancet Rheumatology, Vol. 6, Núm. 6, pp. e374-e383

2022

  1. Complement component C4 structural variation and quantitative traits contribute to sex-biased vulnerability in systemic sclerosis

    npj Genomic Medicine, Vol. 7, Núm. 1

  2. Global Real-World Evidence of Sofosbuvir/Velpatasvir as a Highly Effective Treatment and Elimination Tool in People with Hepatitis C Infection Experiencing Mental Health Disorders

    Viruses, Vol. 14, Núm. 11

2019

  1. GWAS for systemic sclerosis identifies multiple risk loci and highlights fibrotic and vasculopathy pathways

    Nature Communications, Vol. 10, Núm. 1

2017

  1. A Genome-wide Association Study Identifies Risk Alleles in Plasminogen and P4HA2 Associated with Giant Cell Arteritis

    American Journal of Human Genetics, Vol. 100, Núm. 1, pp. 64-74

2016

  1. Brief Report: IRF4 Newly Identified as a Common Susceptibility Locus for Systemic Sclerosis and Rheumatoid Arthritis in a Cross-Disease Meta-Analysis of Genome-Wide Association Studies

    Arthritis and Rheumatology, Vol. 68, Núm. 9, pp. 2338-2344

  2. LILRA3 deficiency is not involved in the giant cell arteritis and systemic sclerosis predisposition

    Clinical and Experimental Rheumatology

2015

  1. Confirmation of CCR6 as a risk factor for anti-topoisomerase I antibodies in systemic sclerosis

    Clinical and Experimental Rheumatology, Vol. 33, pp. 31-35

2014

  1. A genome-wide association study follow-up suggests a possible role for PPARG in systemic sclerosis susceptibility

    Arthritis Research and Therapy, Vol. 16, Núm. 1

  2. Influence of the IL17A locus in giant cell arteritis susceptibility

    Annals of the Rheumatic Diseases, Vol. 73, Núm. 9, pp. 1742-1745

2013

  1. Identification of the PTPN22 functional variant R620W as susceptibility genetic factor for giant cell arteritis

    Annals of the Rheumatic Diseases, Vol. 72, Núm. 11, pp. 1882-1886

  2. Impact of placebo assignment in clinical trials of tic disorders

    Movement Disorders, Vol. 28, Núm. 9, pp. 1288-1292